Skip to main content

Advertisement

SpringerLink
Log in

Cetirizine

A Review of its Use in Allergic Disorders

  • Adis Drug Evaluation
  • Published:
Drugs Aims and scope Submit manuscript

Summary

Abstract

Cetirizine is a selective, second-generation histamine H1 receptor antagonist, with a rapid onset, a long duration of activity and low potential for interaction with drugs metabolised by the hepatic cytochrome P450 system. Cetirizine was generally more effective than other H1 receptor antagonists at inhibiting histamine-induced wheal and flare responses.

Cetirizine is an effective and well tolerated agent for the treatment of symptoms of seasonal allergic rhinitis (SAR), perennial allergic rhinitis (PAR) and chronic idiopathic urticaria (CIU) in adult, adolescent and paediatric patients. In adults with these allergic disorders, cetirizine was as effective as conventional dosages of ebastine (SAR, PAR, CIU), fexofenadine (SAR), loratadine (SAR, CIU) or mizolastine (SAR). This agent was significantly more effective, and with a more rapid onset of action, than loratadine in 2-day studies in environmental exposure units (SAR). In paediatric patients, cetirizine was as at least as effective as chlorphenamine (chlorpheniramine) [SAR], loratadine (SAR, PAR) and oxatomide (CIU) in the short term, and more effective than oxatomide and ketotifen (PAR) in the long term.

Cetirizine was effective in reducing symptoms of allergic asthma in adults and reduced the relative risk of developing asthma in infants with atopic dermatitis sensitised to grass pollen or house dust mite allergens. It had a corticosteroid-sparing effect in infants with severe atopic dermatitis and was effective in ameliorating reactions to mosquito bites in adults.

Cetirizine was well tolerated in adults, adolescents and paediatric patients with allergic disorders. In adult, adolescent and paediatric patients aged 2–11 years, the incidence of somnolence with cetirizine was dose related and was generally similar to that with other second-generation H1 receptor antagonists. Although, its sedative effect was greater than that of fexofenadine in some clinical trials and that of loratadine or fexofenadine in a postmarketing surveillance study. In infants aged 6–24 months, the tolerability profile of cetirizine was similar to that of placebo. Cetirizine did not have any adverse effects on cognitive function in adults, or cognitive function, behaviour or achievement of psychomotor milestones in paediatric patients. Cetirizine was not associated with cardiotoxicity.

Conclusion: Cetirizine is well established in the treatment of symptoms of SAR, PAR or CIU. It demonstrated a corticosteroid-sparing effect and reduced the relative risk of developing asthma in sensitised infants with atopic dermatitis. Cetirizine was effective in the treatment of allergic cough and mosquito bites; however, its precise role in these indications has yet to be clearly established. On the basis of its favourable efficacy and tolerability profile and rapid onset of action, cetirizine provides an important option for the treatment of a wide range of allergic disorders.

Pharmacodynamic Profile

Cetirizine, the carboxylated metabolite of hydroxyzine, exists as a zwitterion, which may partly account for its high hydrogen-binding capacity, limited biotransformation, low-to-moderate lipophilicity and limited ability to cross the blood-brain barrier. It is a highly selective histamine H1 receptor antagonist, with very low affinity for several other types of receptors, including adrenergic and serotoninergic receptors. Single or multiple doses of oral cetirizine 10mg inhibited histamine-induced wheal and flare responses in nonatopic and atopic adults and paediatric patients, and was generally more effective than therapeutic doses of several other antihistamine agents, including ebastine or loratadine. The effect of cetirizine peaked at 4–8 hours and was sustained for at least 24 hours. Cetirizine 5–20mg provided dose-dependent protection against inhaled histamine-induced bronchospasm in patients with asthma. Relative to placebo, nasal airway resistance was reduced in patients with allergic rhinitis and forced expiratory volume in 1 second was increased in patients with asthma.

Cetirizine effectively inhibited allergen-induced wheal and flare responses in atopic and nonatopic volunteers, and at therapeutic doses was at least as effective as standard doses of acrivastine, astemizole, fexofenadine or loratadine. Cetirizine has shown several modulatory effects on the inflammatory response.

Cetirizine 10mg once daily generally did not impair CNS function, although somnolence has been reported in clinical trials. At therapeutic dosages, cetirizine was associated with no or mild impairment of driving and psychometric test performance. Cetirizine did not effect cognitive function in adults, or cognitive function, behaviour or psychomotor milestones in paediatric patients.

Unlike terfenadine or astemizole, cetirizine has not been associated with adverse cardiac effects, either as monotherapy, or when administered in combination with agents that are metabolised by the cytochrome P450 system (e.g. macrolides). In healthy adult volunteers and in paediatric patients, cetirizine had no clinically relevant effect on the QTc interval or ECG parameters. In in vitro studies, cetirizine had no significant effect on cardiac potassium channels.

Pharmacokinetic Profile

Oral cetirizine undergoes rapid, dose-dependent absorption in the gut, with maximum plasma concentrations achieved in approximately 1–2 hours. There was no difference in the bioavailability of the drug with tablet and syrup formulations. Steady-state plasma concentrations are achieved within 2 days and remain stable thereafter, with no clinically relevant accumulation of the drug after 2 weeks’ treatment with oral cetirizine 10mg once daily. Although the presence of food may have some effect on the rate of absorption, there is no difference in the extent of absorption in the fasted and fed states. Approximately 90% of the drug is bound to plasma proteins, mainly albumin.

Cetirizine is extensively distributed throughout the body. Oral cetirizine was rapidly distributed into tear fluid in patients with allergic conjunctivitis and was distributed into breast milk; however, the drug does not readily penetrate the blood-brain barrier.

Cetirizine undergoes minimal metabolism and is predominantly excreted via the urine (70% of the administered dose), with a further 10% of the dose eliminated in the faeces. Small quantities of an O-dealkylation metabolite were excreted in plasma and faeces and two unidentified metabolites have been recovered in the urine. The mean terminal elimination half-life (t1/2β) of cetirizine after a single oral 10mg dose was 6.7–8.6 hours in healthy adult volunteers and the apparent total body clearance (CL) at this dosage was 2.76–5.22 L/h.

The t1/2β in paediatric patients was generally shorter than that in adults; CL values were higher. Although there were significant differences in absorption and elimination values in elderly volunteers relative to younger volunteers, these differences correlated with creatinine clearance rather than with age per se. In patients with mild-to-severe renal impairment, renal clearance and CL are decreased and t1/2β is prolonged relative to individuals with normal renal function, with haemodialysis having no clinically relevant effect on pharmacokinetic parameters. There were significant and clinically relevant changes in absorption and elimination parameters in patients with hepatic impairment relative to those with normal hepatic function.

Cetirizine has a low potential for drug interactions, since it is only minimally metabolised by the liver. Concomitant administration of cetirizine with cimetidine, theophylline or a macrolide (erythromycin or azithromycin) had no clinically relevant effect on the pharmacokinetic profiles of cetirizine or the concomitantly administered agent.

Therapeutic Use

In adult, adolescent and paediatric (aged 2–12 years) patients with seasonal allergic rhinitis (SAR), cetirizine 5 or 10mg once daily was significantly more effective than placebo, according to improvements in total symptom severity (TSS) scores and global assessments of efficacy. Cetirizine was effective in improving multiple domains of health-related quality of life (HR-QOL), assessed according to the Rhinoconjunctivitis Quality of Life Questionnaire (paediatric or adult) and the Activity Impairment-Allergy Specific questionnaire.

In adult and adolescent outpatients with SAR, once-daily doses of cetirizine 5 or 10mg were as effective as standard dosages of ebastine, fexofenadine or mizolastine in the treatment of SAR, according to improvements in TSS score and global assessments of efficacy. However, oral cetirizine 10 mg/day was not as effective as treatment with the corticosteroid fluticasone propionate 200 μg/day administered as a nasal spray. In 2-day studies in an environmental exposure unit, cetirizine 10 mg/day was significantly more effective than loratadine 10 mg/day in treating the symptoms of SAR. The onset of action was more rapid with cetirizine than loratadine (2-day study). In paediatric patients with SAR, cetirizine 10 mg/ day was as effective as chlorphenamine 2mg administered three times daily; cetirizine 10 mg/day, but not loratadine 10 mg/day, was more effective than placebo.

Cetirizine plus montelukast was as effective as topical corticosteroid (budesonide or mometasone) therapy in improving objective and subjective measures of treatment response in SAR, according to data from two small, single-blind, placebo-controlled, crossover studies.

Cetirizine 5 or 10mg once daily was significantly more effective than placebo in adult, adolescent and paediatric patients with perennial allergic rhinitis (PAR). Cetirizine 10 mg/day was as effective as short-term treatment with standard dosages of ebastine, but not long-term treatment (12 months) with budesonide, in adults and adolescents with PAR. Cetirizine significantly improved HR-QOL in adults with PAR (assessed according to the Short-Form 36 Health Survey). Short-term (1–4 weeks) cetirizine was as effective as oxatomide or loratadine in paediatric patients, but long-term treatment (12 weeks) with cetirizine was significantly more effective than oxatomide or ketotifen.

Cetirizine 10mg once daily was significantly more effective than placebo in reducing the symptoms of chronic idiopathic urticaria (CIU), including the number and size of wheals, the number of urticarial episodes and severity of pruritus. Cetirizine 10 mg/day was as effective as standard dosages of hydroxyzine or loratadine. Cetirizine was less effective than montelukast in adults and adolescents with chronic urticaria due to food additives and/or acetylsalicylic acid. The onset of action of cetirizine was faster than that of hydroxyzine. In paediatric patients (aged 2–6 years), cetirizine 5 mg/day was as effective as oxatomide 25 mg/day in reducing symptoms of CIU. Twice-daily administration of cetirizine 0.25 mg/kg was effective in the prevention of acute urticaria in infants aged 12–24 months with atopic dermatitis.

Cetirizine was associated with a reduction in total symptoms of atopic dermatitis in adult, adolescent and paediatric patients, according to data from a limited number of studies. However, at treatment end, its effect was not significantly different from that with placebo, except in recipients of cetirizine 40 mg/day (higher than the recommended dosage). Nevertheless, in infants with severe atopic dermatitis, twice-daily administration of cetirizine 0.25 mg/kg was associated with a significantly greater corticosteroid-sparing effect than placebo.

The symptoms of asthma were relieved to a significantly greater extent with cetirizine 10mg once daily than with placebo in adults with SAR. Cetirizine 0.25 mg/kg twice daily was effective in preventing the development of asthma in infants (aged 10–28 months) with atopic dermatitis who were sensitised to grass pollen or house dust mite.

Data from a limited number of small studies show that cetirizine attenuated local reactions to mosquito bites (initial wheal response and pruritus) and reduced the intensity and frequency of allergic cough in paediatric patients with allergic rhinitis.

Tolerability

In placebo-controlled studies in adults, the most common adverse experiences associated with cetirizine ≤10 mg/day were somnolence (14%), fatigue (6%), dry mouth (5%), pharyngitis (2%) and dizziness (2%). The incidence of these adverse events in placebo recipients was ≤6%. The incidence of discontinuation due to adverse events was similar in patients treated with cetirizine 5 or 10 mg/day or placebo.

In placebo-controlled studies in paediatric patients (aged 6 months to 11 years), cetirizine 5 or 10 mg/day was well tolerated. Headache (11–14%), pharyngitis (3–6%), abdominal pain (4–6%), increased coughing (3–4%), somnolence (2–4%) and epistaxis (2–4%) were commonly reported adverse experiences.

In paediatric patients aged 2–11 years, adverse experiences were more common in cetirizine than placebo recipients. In infants aged 6–24 months, the tolerability profile of cetirizine was similar to that of placebo.

The incidence of somnolence in placebo-controlled studies in adults, adolescents and paediatric patients aged 2–11 years was dose dependent. In infants aged 6–24 months, the incidence of somnolence was similar in cetirizine or placebo recipients.

The incidence of somnolence in adults and adolescents treated with cetirizine was significantly less than that in recipients of hydroxyzine, and was generally similar to that of other second-generation H1 receptor antagonists; although its sedative effect was greater than that of fexofenadine in some clinical studies and that of loratadine or fexofenadine in a postmarketing surveillance study.

Cetirizine administration was not associated with clinically relevant cardiac abnormalities in adults or adolescents (aged ≥12 years) or paediatric patients (aged 6 months to 12 years).

Overdose of cetirizine did not produce clinically significant CNS or cardiovascular toxicity, despite ingestion of a mean dose >4 times the maximum recommended daily dose.

Dosage and Administration

Oral cetirizine, available in a syrup or tablet formulation, is indicated for the relief of symptoms of SAR, PAR and CIU. In the US, cetirizine is approved for use in patients with PAR or CIU (aged ≥6 months) or SAR (aged ≥2 years), whereas in the UK it is approved for use in patients with PAR or CIU (aged ≥6 years) and with SAR (aged ≥2 years). The drug may be taken without regard to food. The recommended dosage varies from country to country, with the dosage adjustments based on age, and the presence of renal and/or hepatic impairment. Cetirizine should be given to pregnant women only if clearly indicated (pregnancy category B rating in the US).

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III
Table IV
Table V
Table VI
Table VII
Table VIII
Table IX
Table X
Fig. 1
Fig. 2
Table XI

Similar content being viewed by others

Notes

  1. Use of brand name is for identification purposes only and does not imply endorsement.

References

  1. Campoli-Richards DM, Buckley MM, Fitton A. Cetirizine: a review of its pharmacological properties and clinical potential in allergic rhinitis, pollen-induced asthma, and chronic urticaria. Drugs 1990 Nov; 40(5): 762–81

    Article  PubMed  CAS  Google Scholar 

  2. Spencer CM, Faulds D, Peters DH. Cetirizine: a reappraisal of its pharmacological properties and therapeutic use in selected allergic disorders. Drugs 1993 Dec; 46(6): 1055–80

    Article  PubMed  CAS  Google Scholar 

  3. Spencer CM, Noble S. Cetirizine: a review of its use in children with allergic disorders. Paediatr Drugs 1999 Jan–Mar; 1(1): 51–73

    Article  PubMed  CAS  Google Scholar 

  4. Wellington K, Jarvis B. Cetirizine/pseudoephedrine. Drugs 2001; 61(15): 2231–40; discussion 2241-2

    Article  PubMed  CAS  Google Scholar 

  5. Wang DY, Hanotte F, De Vos C, et al. Effect of cetirizine, levocetirizine, and dextrocetirizine on histamine-induced nasal response in healthy adult volunteers. Allergy 2001 Apr; 56(4): 339–43

    Article  PubMed  CAS  Google Scholar 

  6. Ermondi G, Caron G, Bouchard G, et al. Molecular-dynamics and NMR investigation of the property space of the zwitterionic antihistamine cetirizine. Helv Chim Acta 2001; 84(2): 360–74

    Article  CAS  Google Scholar 

  7. Plember van Balen G, Caron G, Ermondi G, et al. Lipophilicity behaviour of the zwitterionic antihistamine cetirizine in phosphatidylcholine liposomes/water systems. Pharm Res 2001 May; 18(5): 694–701

    Article  Google Scholar 

  8. Pagliara A, Testa B, Carrupt PA, et al. Molecular properties and pharmacokinetic behavior of cetirizine, a zwitterionic Hi-receptor antagonist. J Med Chem 1998 Mar 12; 41(6): 853–63

    Article  PubMed  CAS  Google Scholar 

  9. Walsh GM, Annunziato L, Frossard N, et al. New insights into the second generation antihistamines. Drugs 2001; 61(2): 207–36

    Article  PubMed  CAS  Google Scholar 

  10. Simons FE, Johnston L, Simons KJ. Clinical pharmacology of the H1-receptor antagonists cetirizine and loratadine in children. Pediatr Allergy Immunol 2000 May; 11(2): 116–9

    Article  PubMed  CAS  Google Scholar 

  11. Bayramgurler D, Bilen N, Apaydyn R, et al. Effects of acrivastine, loratadine and cetirizine on histamine-induced wheal and flare responses. Clin Exp Dermatol 1999 Sep; 24(5): 407–11

    Article  PubMed  CAS  Google Scholar 

  12. Simons FER, McMillan JL, Simons KJ. A double-blind, singledose, crossover comparison of cetirizine, terfenadine, loratadine, astemizole, and chlorpheniramine versus placebo: suppressive effects on histamine-induced wheals and flares during 24 hours in normal subjects. J Allergy Clin Immunol 1990 Oct; 86 (4 Pt 1): 540–7

    Article  PubMed  CAS  Google Scholar 

  13. Humphreys F, Hunter JAA. The effects of astemizole, cetirizine and loratadine on the time course of weal and flare reactions to histamine, codeine and antigen. Br J Dermatol 1991; 125(4): 364–7

    Article  PubMed  CAS  Google Scholar 

  14. Purohit A, Duvernelle C, Melac M, et al. Consistency and efficacy of cetirizine (10 mg) versus ebastine (20 mg) at 4 h on skin reactivity. Eur J Clin Pharmacol 1999 Oct; 55(8): 589–92

    Article  PubMed  CAS  Google Scholar 

  15. Grant JA, Danielson L, Rihoux JP, et al. A double-blind, singledose, crossover comparison of cetirizine, ebastine, epinastine, fexofenadine, terfenadine, and loratadine versus placebo: suppression of histamine-induced wheal and flare response for 24 h in healthy male subjects. Allergy 1999 Jul; 54(7): 700–7

    Article  PubMed  CAS  Google Scholar 

  16. Lever LR, Hill S, Marks R, et al. Effects of cetirizine, loratadine and terfenadine on histamine weal and flare reactions. Skin Pharmacol 1992; 5(1): 29–33

    Article  PubMed  CAS  Google Scholar 

  17. Ramboer I, Bumtbacea R, Lazarescu D, et al. Cetirizine and loratadine: a comparison using the ED50 in skin reactions. J Int Med Res 2000 Mar–Apr; 28(2): 69–77

    PubMed  CAS  Google Scholar 

  18. Persi L, Demoly P, Harris AG, et al. Comparison between nasal provocation tests and skin tests in patients treated with loratadine and cetirizine. J Allergy Clin Immunol 1999 Apr; 103(4): 591–4

    Article  PubMed  CAS  Google Scholar 

  19. Van Neste D, Coussement C, Ghys L, et al. Agonist-antagonist interactions in the skin: comparison of effects of loratadine and cetirizine on skin vascular responses to prick tests with histamine and substance P. J Dermatol Sci 1992 Nov; 4(3): 172–9

    Article  PubMed  Google Scholar 

  20. Rihoux JP, Ghys L, Coulie P. Compared peripheral H1 inhibiting effects of cetirizine 2 HCl and loratadine. Ann Allergy 1990 Aug; 65(2): 139–42

    PubMed  CAS  Google Scholar 

  21. Pechadre JC, Beudin P, Eschalier A, et al. A comparison of central and peripheral effects of cetirizine and loratadine. J Int Med Res 1991 Jul–Aug; 19(4): 289–95

    PubMed  CAS  Google Scholar 

  22. Fadel R, Herpin-Richard N, Dufresne F, et al. Pharmacological modulation by cetirizine and loratadine of antigen and histamine-induced skin weals and flares, and late accumulation of eosinophils. J Int Med Res 1990; 18(5): 366–71

    PubMed  CAS  Google Scholar 

  23. Leroy T, Tasset C, Valentin B, et al. Comparison of the effects of cetirizine and ebastine on the skin response to histamine iontophoresis monitored with laser Doppler flowmetry. Dermatology 1998; 197(2): 146–51

    Article  PubMed  CAS  Google Scholar 

  24. Rivest J, Despontin K, Ghys L, et al. Pharmacological modulation by cetirizine and ebastine of the cutaneous reactivity to histamine. Dermatologica 1991; 183(3): 208–11

    Article  PubMed  CAS  Google Scholar 

  25. Rosenzweig P, Caplain H, Chaufour S, et al. Comparative wheal and flare study of mizolastine vs terfenadine, cetirizine, loratadine and placebo in healthy volunteers. Br J Clin Pharmacol 1995 Nov; 40(5): 459–65

    PubMed  CAS  Google Scholar 

  26. Coulie PJ, Ghys L, Rihoux JP. Cetirizine, oxatomide, ketotifen and placebo. Pharmacological evaluation of their respective anti-H1-histamine, antipruritic and sedating effects. Drug Invest 1991; 3(5): 324–7

    Google Scholar 

  27. Leroy T, van Neste D. Dermal objective pharmacodynamic profile of cetirizine and epinastine: two controlled, randomised, double-blind, crossover studies. Int J Clin Pract 2002 Oct; 56(8): 568–73

    PubMed  CAS  Google Scholar 

  28. Ballmer-Weber BK, Gex-Collet C, Wuthrich B. Inhibition of histamine or allergen-induced wheals by a single dose of acrivastine, fexofenadine or cetirizine. J Investig Allergol Clin Immunol 1999 Nov–Dec; 9(6): 351–5

    PubMed  CAS  Google Scholar 

  29. Furue M, Terao H, Koga T. Effects of cetirizine and epinastine on the skin response to histamine iontophoresis. J Dermatol Sci 2001 Jan; 25(1): 59–63

    Article  PubMed  CAS  Google Scholar 

  30. Purohit A, Duvernelle C, Melac M, et al. Twenty-four hours of activity of cetirizine and fexofenadine in the skin. Ann Allergy Asthma Immunol 2001 Apr; 86(4): 387–92

    Article  PubMed  CAS  Google Scholar 

  31. Purohit A, Melac M, Pauli G, et al. Comparative activity of cetirizine and mizolastine on histamine-induced skin wheal and flare responses at 24 h. Br J Clin Pharmacol 2002 Mar; 53(3): 250–4

    Article  PubMed  CAS  Google Scholar 

  32. Coulie PJ, Ghys L, Rihoux JP. Histamine-induced wheal, flare, and pruritus: inhibition by cetirizine, terfenadine, and placebo. Drug Dev Res 1991; 23(3): 269–74

    Article  CAS  Google Scholar 

  33. Tashkin DP, Brik A, Gong Jr H. Cetirizine inhibition of histamine-induced bronchospasm. Ann Allergy 1987; 59 (6 Pt II): 49–52

    PubMed  CAS  Google Scholar 

  34. Brik A, Tashkin DP, Gong Jr H, et al. Effect of cetirizine, a new histamine H1 antagonist, on airway dynamics and responsiveness to inhaled histamine in mild asthma. J Allergy Clin Immunol 1987 Jul; 80(1): 51–6

    Article  PubMed  CAS  Google Scholar 

  35. Wasserfallen JB, Leuenberger P, Pécoud A. Effect of cetirizine, a new H1 antihistamine, on the early and late allergic reactions in a bronchial provocation test with allergen. J Allergy Clin Immunol 1993 Jun; 91(6): 1189–97

    Article  PubMed  CAS  Google Scholar 

  36. Wood-Baker R, Holgate ST. The comparative actions and adverse effect profile of single doses of H1-receptor antihistamines in the airways and skin of subjects with asthma. J Allergy Clin Immunol 1993 May; 91(5): 1005–14

    Article  PubMed  CAS  Google Scholar 

  37. Ghosh SK, De Vos C, McIlroy I, et al. Effect of cetirizine on histamine- and leukotriene D4-induced bronchoconstriction in patients with atopic asthma. J Allergy Clin Immunol 1991; 87(5): 1010–3

    Article  PubMed  CAS  Google Scholar 

  38. Frossard N, Benabdesselam O, Melac M, et al. Nasal effect of cetirizine and loratadine at 24 hours in patients with allergic rhinitis. Am J Ther 1998 Sep; 5(5): 307–11

    Article  PubMed  CAS  Google Scholar 

  39. Braunstein G, Malaquin F, Fajac I, et al. Inhibition of histamine-induced nasal obstruction by cetirizine in allergic rhinitis. Br J Clin Pharmacol 1992 Apr; 33(4): 445–8

    Article  PubMed  CAS  Google Scholar 

  40. Fadel R, Ramboer I, Chatterjee N, et al. Cetirizine inhibits bradykinin-induced cutaneous wheal and flare in atopic and healthy subjects. Allergy 2000 Apr; 55(4): 382–5

    Article  PubMed  CAS  Google Scholar 

  41. Juhlin L, De Vos C, Rihoux JP. Inhibiting effect of cetirizine on histamine-induced and 48/80-induced wheals and flares, experimental dermographism, and cold-induced urticaria. J Allergy Clin Immunol 1987; 80(4): 599–602

    Article  PubMed  CAS  Google Scholar 

  42. Schoeneich M, Pecoud AR. Effect of cetirizine in a conjunctival provocation test with allergens. Clin Exp Allergy 1990 Mar; 20(2): 171–4

    Article  PubMed  CAS  Google Scholar 

  43. Naclerio RM, Proud D, Kagey-Sobotka A, et al. The effect of cetirizine on early allergic response. Laryngoscope 1989; 99 (6 I): 596–9

    Article  PubMed  CAS  Google Scholar 

  44. Charlesworth EN, Massey WA, Kagey-Sobotka A, et al. Effect of H1 receptor blockade on the early and late response to cutaneous allergen challenge. J Pharmacol Exp Ther 1992; 262(3): 964–70

    PubMed  CAS  Google Scholar 

  45. Taborda-Barata L, Jacobson M, Walker S, et al. Effect of cetirizine and prednisolone on cellular infiltration and cytokine mRNA expression during allergen-induced late cutaneous responses. Clin Exp Allergy 1996 Jan; 26(1): 68–78

    Article  PubMed  CAS  Google Scholar 

  46. Nielsen PN, Skov PS, Poulsen LK, et al. Cetirizine inhibits skin reactions but not mediator release in immediate and developing late-phase allergic cutaneous reactions. A double-blind, placebo-controlled study. Clin Exp Allergy 2001 Sep; 31(9): 1378–84

    CAS  Google Scholar 

  47. Zweiman B, Atkins PC, Moskovitz A, et al. Cellular inflammatory responses during immediate, developing, and established late-phase allergic cutaneous reactions: effects of cetirizine. J Allergy Clin Immunol 1997 Sep; 100(3): 341–7

    Article  PubMed  CAS  Google Scholar 

  48. Ciprandi G, Buscaglia S, Pesce G, et al. Cetirizine reduces inflammatory cell recruitment and ICAM-1 (or CD54) expression on conjunctival epithelium in both early- and late-phase reactions after allergen-specific challenge. J Allergy Clin Immunol 1995 Feb; 95(2): 612–21

    Article  PubMed  CAS  Google Scholar 

  49. Bentley AM, Walker S, Hanotte F, et al. A comparison of the effects of oral cetirizine and inhaled beclomethasone on early and late asthmatic responses to allergen and the associated increase in airways hyperresponsiveness. Clin Exp Allergy 1996 Aug; 26(8): 909–17

    Article  PubMed  CAS  Google Scholar 

  50. Redier H, Chanez P, De Vos C, et al. Inhibitory effect of cetirizine on the bronchial eosinophil recruitment induced by allergen inhalation challenge in allergic patients with asthma. J Allergy Clin Immunol 1992 Aug; 90(2): 215–24

    Article  PubMed  CAS  Google Scholar 

  51. Snyman JR, Sommers DK, Gregorowski MD, et al. Effect of cetirizine, ketotifen and chlorpheniramine on the dynamics of the cutaneous hypersensitivity reaction: a comparative study. Eur J Clin Pharmacol 1992; 42(4): 359–62

    PubMed  CAS  Google Scholar 

  52. Fadel R, Herpin-Richard N, Rihoux JP, et al. Inhibitory effect of cetirizine 2HC1 on eosinophil migration in vivo. Clin Allergy 1987; 17(4): 373–9

    Article  PubMed  CAS  Google Scholar 

  53. Fadel R, David B, Herpin-Richard N, et al. In vivo effects of cetirizine on cutaneous reactivity and eosinophil migration induced by platelet-activating factor (PAF-acether) in man. J Allergy Clin Immunol 1990; 86(31): 314–20

    Article  PubMed  CAS  Google Scholar 

  54. van Steekelenburg J, Clement PA, Beel MH. Comparison of five new antihistamines (H1-receptor antagonists) in patients with allergic rhinitis using nasal provocation studies and skin tests. Allergy 2002 Apr; 57(4): 346–50

    Article  PubMed  Google Scholar 

  55. Okada C, Eda R, Miyagawa H, et al. Effect of cetirizine on human eosinophil Superoxide generation, eosinophil chemotaxis and eosinophil peroxidase in vitro. Int Arch Allergy Immunol 1994; 103(4): 384–90

    Article  PubMed  CAS  Google Scholar 

  56. Michel L, De Vos C, Dubertret L. Cetirizine effects on the cutaneous allergic reaction in humans. Ann Allergy 1990 Dec; 65(6): 512–6

    PubMed  CAS  Google Scholar 

  57. Michel L, De Vos C, Rihoux JP, et al. Inhibitory effect of oral cetirizine on in vivo antigen-induced histamine and PAF-acether release and eosinophil recruitment in human skin. J Allergy Clin Immunol 1988 Jul; 82(1): 101–9

    Article  PubMed  CAS  Google Scholar 

  58. Mincarini M, Cagnoni F, Canonica GW, et al. Quantitative flow cytometric analysis of the effects of cetirizine on the expression of ICAM-1/CD54 on primary cultured nasal cells. Allergy 2000 Mar; 55(3): 226–31

    Article  PubMed  CAS  Google Scholar 

  59. Albanesi C, Pastore S, Fanales-Belasio E, et al. Cetirizine and hydrocortisone differentially regulate ICAM-1 expression and chemokine release in cultured human keratinocytes. Clin Exp Allergy 1998 Jan; 28(1): 101–9

    Article  PubMed  CAS  Google Scholar 

  60. Ambrosch A, Borgmann S, Rihoux JP, et al. Effect of the H1-receptor antagonist cetirizine on the stimulated expression of adhesion molecules and the activation of NFκB in human endothelial cells. Int Arch Allergy Immunol 2001; 124(1–3): 362–4

    Article  CAS  Google Scholar 

  61. Campbell A, Chanal I, Czarlewski W, et al. Reduction of soluble ICAM-1 levels in nasal secretion by H1-blockers in seasonal allergic rhinitis. Allergy 1997 Oct; 52(10): 1022–5

    Article  PubMed  CAS  Google Scholar 

  62. Fasce L, Ciprandi G, Pronzato C, et al. Cetirizine reduces ICAM-I on epithelial cells during nasal minimal persistent inflammation in asymptomatic children with mite-allergic asthma. Int Arch Allergy Immunol 1996 Mar; 109(3): 272–6

    Article  PubMed  CAS  Google Scholar 

  63. Boone M, Lespagnard L, Renard N, et al. Adhesion molecule profiles in atopic dermatitis vs. allergic contact dermatitis: pharmacological modulation by cetirizine. J Eur Acad Dermatol Venereol 2000 Jul; 14(4): 263–6

    CAS  Google Scholar 

  64. Sehmi R, Walsh GM, Hartneil A, et al. Modulation of human eosinophil chemotaxis and adhesion by anti-allergic drugs in vitro. Pediatr Allergy Immunol 1993; 4 (4 Suppl. 1): 13–8

    Article  PubMed  CAS  Google Scholar 

  65. Kyan-Aung U, Hallsworth M, Haskard D, et al. The effects of cetirizine on the adhesion of human eosinophils and neutrophils to cultured human umbilical vein endothelial cells. J Allergy Clin Immunol 1992 Aug; 90(2): 270–2

    Article  PubMed  CAS  Google Scholar 

  66. Thomson L, Blaylock MG, Sexton DW, et al. Cetirizine and levocetirizine inhibit eotaxin-induced eosinophil transendothelial migration through human dermal or lung microvascular endothelial cells. Clin Exp Allergy 2002 Aug; 32(8): 1187–92

    Article  PubMed  CAS  Google Scholar 

  67. Bae S-J, Tanaka Y, Ogawa F, et al. Inhibitory effect of cetirizine on histamine-induced eotaxin production in normal human fibroblasts. Curr Ther Res Clin Exp 2002; 63(2): 128–40

    Article  CAS  Google Scholar 

  68. Andreozzi P, Magrini L, Bagalino A, et al. Eotaxin serum levels in allergic rhinitis: effect of antihistamine treatment [abstract no. P339]. Allergy 1999; 54 Suppl. 52: 160

    Google Scholar 

  69. Jacobi HH, Skov PS, Poulsen LK, et al. Histamine and tryptase in nasal lavage fluid after allergen challenge: effect of 1 week of pretreatment with intranasal azelastine or systemic cetirizine. J Allergy Clin Immunol 1999 May; 103 (5 Pt 1): 768–72

    Article  PubMed  CAS  Google Scholar 

  70. Bruno G, Andreozzi P, Bracchitta S, et al. Serum tryptase in allergic rhinitis: effect of cetirizine and fluticasone propionate treatment. Clin Ter 2001 Sep–Oct; 152(5): 299–303

    PubMed  CAS  Google Scholar 

  71. Bruno G, Andreozzi P, Magrini L, et al. Serum tryptase in allergic rhinitis: effect of cetirizine treatment. Int J Immunopathol Pharmacol 2001 Sep–Dec; 14(3): 147–52

    PubMed  CAS  Google Scholar 

  72. Arnold R, Rihoux J, Konig W. Cetirizine counter-regulates interleukin-8 release from human epithelial cells (A549). Clin Exp Allergy 1999 Dec; 29(12): 1681–91

    Article  PubMed  CAS  Google Scholar 

  73. Lippert U, Moller A, Welker P, et al. Inhibition of cytokine secretion from human leukemic mast cells and basophils by H1- and H2-receptor antagonists. Exp Dermatol 2000 Apr; 9(2): 118–24

    Article  PubMed  CAS  Google Scholar 

  74. Koller M, Hilger RA, Rihoux JP, et al. Cetirizine exerts anti-inflammatory effects on human neutrophils. Int Arch Allergy Immunol 1996 May; 110(1): 52–6

    Article  PubMed  CAS  Google Scholar 

  75. Cheria-Sammari S, Aloui R, Gormand F, et al. Leukotriene B4 production by blood neutrophils in allergic rhinitis: effects of cetirizine. Clin Exp Allergy 1995 Aug; 25(8): 729–36

    Article  PubMed  CAS  Google Scholar 

  76. Di Gioacchino M, Verna N, Cavallucci E, et al. Steroid and antihistamines modulate RANTES release in cultured peripheral blood mononuclear cells of atopic patients. Int J Immunopathol Pharmacol 2002 Jan; 15(1): 27–34

    PubMed  Google Scholar 

  77. Bruno G, Andreozzi P, Graf U, et al. Cetirizine, a secondgeneration H1 antagonist, modulates Rantes and MCP-1 levels in allergic rhinitis. Int J Immunopathol Pharmacol 2002 May–Aug; 15(2): 113–8

    PubMed  CAS  Google Scholar 

  78. Dobashi K, Iizuka K, Houjou S, et al. Effect of cetirizine on antigen-induced tracheal contraction of passively sensitized guinea pigs. Ann Allergy Asthma Immunol 1996 Oct; 77(4): 310–8

    Article  PubMed  CAS  Google Scholar 

  79. Jin H-R, Okamoto Y, Matsuzaki Z, et al. Cetirizine decreases interleukin-4, interleukin-5, and interferon-gamma gene expressions in nasal-associated lymphoid tissue of sensitized mice. Am J Rhinol 2002; 16(1): 43–8

    PubMed  Google Scholar 

  80. Charlesworth EN, Kagey-Sobotka A, Norman PS, et al. Effect of cetirizine on mast cell-mediator release and cellular traffic during the cutaneous late-phase reaction. J Allergy Clin Immunol 1989 May; 83(5): 905–12

    Article  PubMed  CAS  Google Scholar 

  81. Okayama Y, Benyon RC, Lowman MA, et al. In vitro effects of H1-antihistamines on histamine and PGD2 release from mast cells of human lung, tonsil, and skin. Allergy 1994 Apr; 49(4): 246–53

    Article  PubMed  CAS  Google Scholar 

  82. Fabre JM, Marty-Ané C, Alauzen M, et al. Pharmacologic heterogeneity of human lung and colon cells: effect of terfenadine and cetirizine. Allergy 1995 Apr; 50(4): 362–5

    Article  PubMed  CAS  Google Scholar 

  83. Roch-Arveiller M, Tissot M, Idohou N, et al. In vitro effect of cetirizine on PGE2 release by rat peritoneal macrophages and human monocytes. Agents Actions 1994 Nov; 43(1–2): 13–6

    Article  PubMed  CAS  Google Scholar 

  84. Jinquan T, Reimert CM, Deleuran B, et al. Cetirizine inhibits the in vitro and ex vivo chemotactic response of T lymphocytes and monocytes. J Allergy Clin Immunol 1995 May; 95(5 Pt 1): 979–86

    Article  PubMed  CAS  Google Scholar 

  85. Tashiro M, Mochizuki H, Iwabuchi K, et al. Roles of histamine in regulation of arousal and cognition: functional neuroimaging of histamine H1 receptors in human brain. Life Sci 2002 Dec; 72(4–5): 409–14

    Article  PubMed  CAS  Google Scholar 

  86. Gengo FM, Dabronzo J, Yurchak A, et al. The relative antihistaminic and psychomotor effects of hydroxyzine and cetirizine. Clin Pharmacol Ther 1987; 42(3): 265–72

    Article  PubMed  CAS  Google Scholar 

  87. Volkerts ER, Van Willigenburg APP, Van Laar MW, et al. Does cetirizine belong to the new generation of antihistamines? An investigation into its acute and subchronic effects on highway driving, psychometric test performance and daytime sleepiness. Hum Psychopharmacol 1992; 7(4): 227–38

    Article  CAS  Google Scholar 

  88. Walsh JK, Muehlbach MJ, Schweitzer PK. Simulated assembly line performance following ingestion of cetirizine or hydroxyzine. Ann Allergy 1992 Sep; 69(3): 195–200

    PubMed  CAS  Google Scholar 

  89. Gengo FM, Gabos C, Mechtler L. Quantitative effects of cetirizine and diphenhydramine on mental performance measured using an automobile driving simulator. Ann Allergy 1990; 64(6): 520–6

    PubMed  CAS  Google Scholar 

  90. Vermeeren A, Ramaekers JG, O’Hanlon JF. Effects of emedastine and cetirizine, alone and with alcohol, on actual driving of males and females. J Psychopharmacol 2002 Mar; 16(1): 57–64

    Article  PubMed  CAS  Google Scholar 

  91. Stevenson J, Cornah D, Evrard P, et al. Long-term evaluation of the impact of the H1-receptor antagonist cetirizine on the behavioral, cognitive, and psychomotor development of very young children with atopic dermatitis. Pediatr Res 2002 Aug; 52(2): 251–7

    Article  PubMed  CAS  Google Scholar 

  92. Shamsi Z, Kimber S, Hindmarch I. An investigation into the effects of cetirizine on cognitive function and psychomotor performance in healthy volunteers. Eur J Clin Pharmacol 2001 Mar; 56(12): 865–71

    Article  PubMed  CAS  Google Scholar 

  93. Schweitzer PK, Muehlbach MJ, Walsh JK. Sleepiness and performance during three-day administration of cetirizine or diphenhydramine. J Allergy Clin Immunol 1994 Oct; 94(4): 716–24

    Article  PubMed  CAS  Google Scholar 

  94. Nicholson AN, Turner C. Central effects of the H1-antihistamine, cetirizine. Aviat Space Environ Med 1998 Feb; 69(2): 166–71

    PubMed  CAS  Google Scholar 

  95. Hindmarch, Johnson S, Meadows R, et al. The acute and subchronic effects of levocetirizine, cetirizine, loratadine, promethazine and placebo on cognitive function, psychomotor performance, and weal and flare. Curr Med Res Opin 2001; 17(4): 241–55

    PubMed  CAS  Google Scholar 

  96. Gandon JM, Allain H. Lack of effect of single and repeated doses of levocetirizine, a new antihistamine drug, on cognitive and psychomotor functions in healthy volunteers. Br J Clin Pharmacol 2002 Jul; 54(1): 51–8

    Article  PubMed  CAS  Google Scholar 

  97. Ramaekers JG, Uiterwijk MMC, O’Hanlon JF. Effects of loratadine and cetirizine on actual driving and psychometric test performance, and EEG during driving. Eur J Clin Pharmacol 1992; 42(4): 363–9

    PubMed  CAS  Google Scholar 

  98. Levander S, Stahle-Backdahl M, Hagermark O. Peripheral antihistamine and central sedative effects of single and continuous oral doses of cetirizine and hydroxyzine. Eur J Clin Pharmacol 1991; 41(5): 435–9

    Article  PubMed  CAS  Google Scholar 

  99. Simons FE, Fraser TG, Reggin JD, et al. Individual differences in central nervous system response to antihistamines (Hi-receptor antagonists). Ann Allergy Asthma Immunol 1995 Dec; 75 (6 Pt 1): 507–14

    PubMed  CAS  Google Scholar 

  100. Simons FE, Fraser TG, Reggin JD, et al. Comparison of the central nervous system effects produced by six H1-receptor antagonists. Clin Exp Allergy 1996 Sep; 26(9): 1092–7

    Article  PubMed  CAS  Google Scholar 

  101. Simons FE, Fraser TG, Maher J, et al. Central nervous system effects of H1-receptor antagonists in the elderly. Ann Allergy Asthma Immunol 1999 Feb; 82(2): 157–60

    Article  PubMed  CAS  Google Scholar 

  102. Spaeth J, Klimek L, Mosges R. Sedation in allergic rhinitis is caused by the condition and not by antihistamine treatment. Allergy 1996 Dec; 51(12): 893–906

    PubMed  CAS  Google Scholar 

  103. Sannita WG, Crimi E, Riela S, et al. Cutaneous antihistaminic action of cetirizine and dose-related EEG concomitants of sedation in man. Eur J Pharmacol 1996 Apr 4; 300(1–2): 33–41

    Article  PubMed  CAS  Google Scholar 

  104. Patat A, Stubbs D, Dunmore C, et al. Lack of interaction between two antihistamines, mizolastine and cetirizine, and ethanol in psychomotor and driving performance in healthy subjects. Eur J Clin Pharmacol 1995; 48(2): 143–50

    Article  PubMed  CAS  Google Scholar 

  105. Sale M, Woolsey R, Thakker K, et al. Effects of cetirizine and erythromycin, alone and in combination on QT interval and pharmacokinetics in healthy subjects [abstract no. P15]. Ann Allergy Asthma Immunol 1996 Jan; 76(1): 93

    Google Scholar 

  106. Sale ME, Barbey JT, Woosley RL, et al. The electrocardiographic effects of cetirizine in normal subjects. Clin Pharmacol Ther 1994 Sep; 56(3): 295–301

    Article  PubMed  CAS  Google Scholar 

  107. Winder JA, Noonan MJ, Lumry WR, et al. Absence of QT(c) prolongation with cetirizine in children aged 6 to 11 years. Pediatr Asthma Allergy Immunology 1996; 10(4): 181–90

    Article  Google Scholar 

  108. Simons FE. Prospective, long-term safety evaluation of the H1-receptor antagonist cetirizine in very young children with atopic dermatitis: ET AC Study Group. Early Treatment of the Atopic Child. J Allergy Clin Immunol 1999 Aug; 104 (2 Pt 1): 433–40

    Article  PubMed  CAS  Google Scholar 

  109. Simons FE, Silas P, Portnoy JM, et al. Safety of cetirizine in infants 6 to 11 months of age: a randomized, double-blind, placebo-controlled study. J Allergy Clin Immunol 2003 Jun; 111(6): 1244–8

    Article  PubMed  CAS  Google Scholar 

  110. Sale M, Woosley R, Thakker K, et al. A randomized, placebocontrolled, multiple-dose study to evaluate the electrocardiographic and pharmacokinetic interactions of azithromycin and cetirizine [abstract no P14. Ann Allergy Asthma Immunol 1996 Jan; 76(1): 93

    Google Scholar 

  111. Weissenburger J, Noyer M, Cheymol G, et al. Electrophysiological effects of cetirizine, astemizole and D-sotalol in a canine model of long QT syndrome. Clin Exp Allergy 1999 Jul; 29 Suppl. 3: 190–6

    Article  PubMed  CAS  Google Scholar 

  112. Taglialatela M, Pannaccione A, Castaldo P, et al. Molecular basis for the lack of HERG K+ channel block-related cardiotoxicity by the H1 receptor blocker cetirizine compared with other second-generation antihistamines. Mol Pharmacol 1998 Jul; 54(1): 113–21

    PubMed  CAS  Google Scholar 

  113. Carmeliet E. Effects of cetirizine on the delayed K+ currents in cardiac cells: comparison with terfenadine. Br J Pharmacol 1998 Jun; 124(4): 663–8

    Article  PubMed  CAS  Google Scholar 

  114. Barbey JT, Anderson M, Ciprandi G, et al. Cardiovascular safety of second-generation antihistamines. Am J Rhinol 1999 May–Jun; 13(3): 235–43

    Article  PubMed  CAS  Google Scholar 

  115. Gillard M, van der Perren C, Moguilevsky N, et al. Binding characteristics of cetirizine and levocetirizine to human H(l) histamine receptors: contribution of Lys(191) and Thr(194). Mol Pharmacol 2002 Feb; 61(2): 391–9

    Article  PubMed  CAS  Google Scholar 

  116. Snyder SH, Snowman AM. Receptor effects of cetirizine. Ann Allergy 1987 Dec; 59 (6 Pt II): 4–8

    PubMed  CAS  Google Scholar 

  117. Hayashi S, Hashimoto S. Anti-inflammatory actions of new antihistamines. Clin Exp Allergy 1999 Dec; 29(12): 1593–6

    Article  PubMed  CAS  Google Scholar 

  118. Walsh GM. The effects of cetirizine on the function of inflammatory cells involved in the allergic response. Clin Exp Allergy 1997 Nov; 27 Suppl. 2: 47–53; discussion 54-6

    Article  PubMed  CAS  Google Scholar 

  119. Walsh GM. The clinical relevance of the anti-inflammatory properties of antihistamines. Allergy 2000; 55 Suppl. 60: 53–61

    Article  PubMed  Google Scholar 

  120. Shamsi H, Hindmarch I. Sedation and antihistamines: a review of inter-drug differences using proportional impairment ratios. Hum Psychopharmacol 2000 Oct; 15(S1): S3–S30

    Article  PubMed  CAS  Google Scholar 

  121. Baltes E, Coupez R, Giezek H, et al. Absorption and disposition of levocetirizine, the eutomer of cetirizine, administered alone or as cetirizine to healthy volunteers. Fundam Clin Pharmacol 2001 Aug; 15(4): 269–77

    Article  PubMed  CAS  Google Scholar 

  122. Matzke GR, Yeh J, Awni WM, et al. Pharmacokinetics of cetirizine in the elderly and patients with renal insufficiency. Ann Allergy 1987 Dec; 59 (6 Pt 2): 25–30

    PubMed  CAS  Google Scholar 

  123. Muscara MN, de Nucci G. Comparative bioavailability of single doses of tablet formulations of cetirizine dihydrochloride in healthy male volunteers. Int J Clin Pharmacol Ther 1995 Jan; 33(1): 27–31

    PubMed  CAS  Google Scholar 

  124. Sasa M, Naito M, Kojima T. Pharmacokinetics of single and multiple doses of a new antiallergic drug, cetirizine, and examination of its safety [in Japanese]. Jpn J Clin Pharmacol Ther 1995 Jun; 26(2): 509–22

    Article  CAS  Google Scholar 

  125. Wood SG, John BA, Chasseaud LF, et al. The metabolism and pharmacokinetics of 14C-cetirizine in humans. Ann Allergy 1987; 59 (6 Pt II): 31–4

    PubMed  CAS  Google Scholar 

  126. Desager JP, Dab I, Horsmans Y, et al. A pharmacokinetic evaluation of the second-generation H1-receptor antagonist cetirizine in very young children. Clin Pharmacol Ther 1993; 53(4): 431–5

    Article  PubMed  CAS  Google Scholar 

  127. Špičák V, Dab I, Hulhoven R, et al. Pharmacokinetics and pharmacodynamics of cetirizine in infants and toddlers. Clin Pharmacol Ther 1997 Mar; 61(3): 325–30

    Article  PubMed  Google Scholar 

  128. Pariente-Khayat A, Rey E, Dubois MC, et al. Pharmacokinetics of cetirizine in 2- to 6-year-old children. Int J Clin Pharmacol Ther 1995 Jun; 33(6): 340–4

    PubMed  CAS  Google Scholar 

  129. Watson WTA, Simons KJ, Chen XY, et al. Cetirizine: a pharmacokinetic and pharmacodynamic evaluation in children with seasonal allergic rhinitis. J Allergy Clin Immunol 1989; 84 (4 Pt 1): 457–64

    Article  PubMed  CAS  Google Scholar 

  130. Awni WM, Yeh J, Halstenson CE, et al. Effect of haemodialysis on the pharmacokinetics of cetirizine. Eur J Clin Pharmacol 1990; 38(1): 67–9

    Article  PubMed  CAS  Google Scholar 

  131. Simons FER, Watson WTA, Minuk GY, et al. Cetirizine pharmacokinetics and pharmacodynamics in primary biliary cirrhosis. J Clin Pharmacol 1993 Oct; 33(10): 949–54

    PubMed  CAS  Google Scholar 

  132. Pfizer Inc. Zyrtec® (cetirizine hydrochloride): tablets and syrup for oral use [US prescribing information]. New York: Pfizer Inc., 2003

    Google Scholar 

  133. Fraser TG, Simons FE, Simons KJ. Cetirizine and hydroxyzine: minimal accumulation at steady-state following once daily dosing in adults [abstract no. 901]. J Allergy Clin Immunol 1999; 103 (Pt 2): S234

    Google Scholar 

  134. Urien S, Jolliet P, Morin Ch, et al. Cetirizine blood binding and expected pharmacological and pathological variations [abstract no. 1149]. Allergy Clin Immunol News 1994; Suppl. 2: 321

    Google Scholar 

  135. Grumetto L, Cennamo G, Del Prete A, et al. Pharmacokinetics of cetirizine in tear fluid after a single oral dose. Clin Pharmacokinet 2002; 41(7): 525–31

    Article  PubMed  CAS  Google Scholar 

  136. Cetirizine hydrochloride. In: McEnvoy GK, editor. American Hospital Formulary Services Drug Information 2003. Bethesda (MD): American Society of Health-System Pharmacists, 2003: 12–7

  137. Noiri E, Ozawa H, Fuμta T, et al. Pharmacokinetics of cetirizine in chronic hemodialysis patients: multiple-dose study. Nephron 2001 Sep; 89(1): 101–4

    Article  PubMed  CAS  Google Scholar 

  138. Nicolas JM, Whomsley R, Collart P, et al. In vitro inhibition of human liver drug metabolizing enzymes by second generation antihistamines. Chem Biol Interact 1999 Nov 15; 123(1): 63–79

    Article  PubMed  CAS  Google Scholar 

  139. Simons FE, Sussman GL, Simons KJ. Effect of the H2-antagonist cimetidine on the pharmacokinetics and pharmacodynamics of the H1-antagonists hydroxyzine and cetirizine in patients with chronic urticaria. J Allergy Clin Immunol 1995 Mar; 95(3): 685–93

    Article  PubMed  CAS  Google Scholar 

  140. Hulhoven R, Desager JP, Harvengt C. Lack of clinically relevant interaction of cetirizine on theophylline disposition in healthy subjects: a placebo-controlled study. Am J Ther 1995 Jan; 2(1): 71–4

    Article  PubMed  Google Scholar 

  141. Rosenwasser LJ. Treatment of allergic rhinitis. Am J Med 2002 Dec 16; 113 Suppl. 9A: 17S–24S

    Article  PubMed  CAS  Google Scholar 

  142. Ten Eick AP, Blumer JL, Reed MD. Safety of antihistamines in children. Drug Saf 2001; 24(2): 119–47

    Article  PubMed  Google Scholar 

  143. Backhouse CI, Renton R, Fidler C, et al. Multicentre, double-blind comparison of terfenadine and cetirizine in patients with seasonal allergic rhinitis. Br J Clin Pract 1990 Mar; 44(3): 88–91

    PubMed  CAS  Google Scholar 

  144. Berkowitz RB, Dockhorn R, Lockey R, et al. Comparison of efficacy, safety, and skin test inhibition of cetirizine and astemizole. Ann Allergy Asthma Immunol 1996 Apr; 76(4): 363–8

    Article  PubMed  CAS  Google Scholar 

  145. Falliers CJ, Brandon ML, Buchman E, et al. Double-blind comparison of cetirizine and placebo in the treatment of seasonal rhinitis. Ann Allergy 1991; 66(3): 257–62

    PubMed  CAS  Google Scholar 

  146. Gehanno P, Bremard-Oury C, Zeisser P. Comparison of ebastine to cetirizine in seasonal allergic rhinitis in adults. Ann Allergy Asthma Immunol 1996 Jun; 76(6): 507–12

    Article  PubMed  CAS  Google Scholar 

  147. Hampel F, Ratner P, Mansfield L, et al. Fexofenadine hydrochloride, 180 mg, exhibits equivalent efficacy to cetirizine, 10 mg, with less drowsiness in patients with moderate-to-severe seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2003 Oct; 91(4): 354–61

    Article  PubMed  CAS  Google Scholar 

  148. Howarth PH, Stern MA, Roi L, et al. Double-blind, placebocontrolled study comparing the efficacy and safety of fexofenadine hydrochloride (120 and 180 mg once daily) and cetirizine in seasonal allergic rhinitis. J Allergy Clin Immunol 1999 Nov; 104(5): 927–33

    Article  PubMed  CAS  Google Scholar 

  149. Lockey RF, Widlitz MD, Mitchell DQ, et al. Comparative study of cetirizine and terfenadine versus placebo in the symptomatic management of seasonal allergic rhinitis. Ann Allergy Asthma Immunol 1996 May; 76(5): 448–54

    Article  PubMed  CAS  Google Scholar 

  150. Murray JJ, Nathan RA, Bronsky EA, et al. Comprehensive evaluation of cetirizine in the management of seasonal allergic rhinitis: impact on symptoms, quality of life, productivity, and activity impairment. Allergy Asthma Proc 2002 Nov–Dec; 23(6): 391–8

    PubMed  CAS  Google Scholar 

  151. Noonan MJ, Raphael GD, Nayak A, et al. The health-related quality of life effects of once-daily cetirizine HC1 in patients with seasonal allergic rhinitis: a randomized double-blind, placebo-controlled trial. Clin Exp Allergy 2003 Mar; 33(3): 351–8

    Article  PubMed  CAS  Google Scholar 

  152. Sabbah A, Daele J, Wade AG, et al. Comparison of the efficacy, safety, and onset of action of mizolastine, cetirizine, and placebo in the management of seasonal allergic rhinoconjunctivitis. MIZOCET Study Group. Ann Allergy Asthma Immunol 1999 Oct; 83(4): 319–25

    Article  CAS  Google Scholar 

  153. Vervloet D, Charpin D, Desfougeres JL. Intranasal fluticasone once daily compared with once-daily cetirizine in the treatment of seasonal allergic rhinitis. Results of a multicentre, double-blind study. Clin Drug Invest 1997 Jun; 13(6): 291–8

    CAS  Google Scholar 

  154. Grant JA, Nicodemus CF, Findlay SR, et al. Cetirizine in patients with seasonal rhinitis and concomitant asthma: prospective, randomized, placebo-controlled trial. J Allergy Clin Immunol 1995 May; 95 (5 Pt 1): 923–32

    Article  PubMed  CAS  Google Scholar 

  155. Davies BH. Prophylactic treatment of seasonal allergic rhinitis. Clin Ther 1991 Jan; 13: 87–91

    PubMed  CAS  Google Scholar 

  156. Day JH, Briscoe M, Rafeiro E, et al. Comparative onset of action and symptom relief with cetirizine, loratadine, or placebo in an environmental exposure unit in subjects with seasonal allergic rhinitis: confirmation of a test system. Ann Allergy Asthma Immunol 2001 Dec; 87(6): 474–81

    Article  PubMed  CAS  Google Scholar 

  157. Day JH, Briscoe M, Widlitz MD. Cetirizine, loratadine, or placebo in subjects with seasonal allergic rhinitis: effects after controlled ragweed pollen challenge in an environmental exposure unit. J Allergy Clin Immunol 1998 May; 101(5): 638–45

    Article  PubMed  CAS  Google Scholar 

  158. Meltzer EO, Weiler JM, Widlitz MD. Comparative outdoor study of the efficacy, onset and duration of action, and safety of cetirizine, loratadine, and placebo for seasonal allergic rhinitis. J Allergy Clin Immunol 1996 Feb; 97(2): 617–26

    Article  PubMed  CAS  Google Scholar 

  159. Allegra L, Paupe J, Wieseman HG, et al. Cetirizine for seasonal allergic rhinitis in children aged 2–6 years. A double-blind comparison with placebo. Pediatr Allergy Immunol 1993; 4(3): 157–61

    CAS  Google Scholar 

  160. Masi M, Candiani R, van de Venne H. A placebo-controlled trial of cetirizine in seasonal allergic rhino-conjunctivitis in children aged 6 to 12 years. Pediatr Allergy Immunol 1993; 4 Suppl. 4: 47–52

    Article  PubMed  CAS  Google Scholar 

  161. Pearlman DS, Lumry WR, Winder JA, et al. Once-daily cetirizine effective in the treatment of seasonal allergic rhinitis in children aged 6 to 11 years: a randomized, double-blind, placebo-controlled study. Clin Pediatr (Phila) 1997 Apr; 36(4): 209–15

    Article  CAS  Google Scholar 

  162. Ratner P, Gillman S, LaForce C, et al. A randomized, double blind, parallel group, placebo controlled, multicenter study of the efficacy and safety of Zyrtec (cetirizine HCL) syrup vs. Claritin (loratadine) syrap vs. placebo in the treatment of children with seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2003 Jan; 90(1): 121–2

    Google Scholar 

  163. Tinkelman DG, Kemp J, Mitchell DQ, et al. Treatment of seasonal allergic rhinitis in children with cetirizine or chlorpheniramine: a multicenter study. Pediatr Asthma Allergy Immunol 1996; 10(1): 9–17

    Article  Google Scholar 

  164. Bertrand B, Jamart J, Marchal JL, et al. Cetirizine and pseudoephedrine retard alone and in combination in the treatment of perennial allergic rhinitis: a double-blind multicentre study. Rhinology 1996 Jun; 34(2): 91–6

    PubMed  CAS  Google Scholar 

  165. Chaweewan B, Jareonchai P, Dhorranintra B. A clinical comparison of cetirizine versus astemizole in perennial allergic rhinitis. Drug Invest 1993 Apr; 5(4): 222–8

    Article  Google Scholar 

  166. Mansmann Jr HC, Altman RA, Berman BA, et al. Efficacy and safety of cetirizine therapy in perennial allergic rhinitis. Ann Allergy 1992 Apr; 68(4): 348–53

    PubMed  Google Scholar 

  167. Murris-Espin M, Melac M, Charpentier JC, et al. Comparison of efficacy and safety of cetirizine and ebastine in patients with perennial allergic rhinitis. Ann Allergy Asthma Immunol 1998 May; 80(5): 399–403

    Article  PubMed  CAS  Google Scholar 

  168. Renton R, Fidler C, Rosenberg R. Multicenter, crossover study of the efficacy and tolerability of terfenadine, 120 mg, versus cetirizine, 10 mg, in perennial allergic rhinitis. Ann Allergy 1991 Oct; 67(4): 416–20

    PubMed  CAS  Google Scholar 

  169. Rinne J, Simola M, Malmberg H, et al. Early treatment of perennial rhinitis with budesonide or cetirizine and its effect on long-term outcome. J Allergy Clin Immunol 2002 Mar; 109(3): 426–32

    Article  PubMed  CAS  Google Scholar 

  170. Baelde Y, Dupont P. Cetirizine in children with chronic allergic rhinitis. A multicentre double-blind study of two doses of cetirizine and placebo. Drug Invest 1992; 4(6): 466–72

    Google Scholar 

  171. De Benedictis FM, Forenza N, Armenio L, et al. Efficacy and safety of cetirizine and oxatomide in young children with perennial allergic rhinitis: a 10 day, multicenter, double-blinded, randomized, parallel-group study. Pediatr Asthma Allergy Immunol 1997; 11(2): 119–28

    Article  Google Scholar 

  172. JobstS, van den Wijngaart W, Schubert A, et al. Assessment of the efficacy and safety of three dose levels of cetirizine given once daily in children with perennial allergic rhinitis. Allergy 1994 Sep; 49(8): 598–604

    Article  Google Scholar 

  173. Lai DS, Lue KH, Hsieh JC, et al. The comparison of the efficacy and safety of cetirizine, oxatomide, ketotifen, and a placebo for the treatment of childhood perennial allergic rhinitis. Ann Allergy Asthma Immunol 2002 Dec; 89(6): 589–98

    Article  PubMed  CAS  Google Scholar 

  174. Sienra-Monge JJ, Gazca-Aguilar A, Del Rio-Navarro B. Double-blind comparison of cetirizine and loratadine in children ages 2 to 6 years with perennial allergic rhinitis. Am J Ther 1999 May; 6(3): 149–55

    Article  PubMed  CAS  Google Scholar 

  175. Caiaffa MF, Iudice A, Macchia L, et al. Multicenter double-blind comparative study of terfenadine and cetirizine in hay fever. J Investig Allergol Clin Immunol 1992 May–Jun; 2(3): 162–6

    PubMed  CAS  Google Scholar 

  176. Charpin D, Godard P, Garay RP, et al. A multicenter clinical study of the efficacy and tolerability of azelastine nasal spray in the treatment of seasonal allergic rhinitis: a comparison with oral cetirizine. Eur Arch Otorhinolaryngol 1995; 252(8): 455–8

    Article  PubMed  CAS  Google Scholar 

  177. Nunes C, Ladeira S. Double-blind study of cetirizine and loratadine versus placebo in patients with allergic rhinitis. J Investig Allergol Clin Immunol 2000 Jan–Feb; 10(1): 20–3

    PubMed  CAS  Google Scholar 

  178. Jain RK. Cetirizine and astemizole in allergic rhinitis: a comparative study. Indian Journal of Otolaryngology 1999; 51(3): 94–8

    Article  CAS  Google Scholar 

  179. Harcup JW, Hawkes G, Saul PA. The efficacy and sedative profile of astemizole and cetirizine in the treatment of grass pollen hayfever in general practice. Br J Clin Pract 1993; 47(3): 131–5

    PubMed  CAS  Google Scholar 

  180. Bonifazi F, Provinciali L, Antonicelli L, et al. Comparative study of terfenadine and cetirizine in hay fever: assessment of efficacy and central nervous system effects. J Investig Allergol Clin Immunol 1995 Jan–Feb; 5(1): 40–6

    PubMed  CAS  Google Scholar 

  181. Day JH, Briscoe MP, Clark RH, et al. Onset of action and efficacy of terfenadine, astemizole, cetirizine, and loratadine for the relief of symptoms of allergic rhinitis. Ann Allergy Asthma Immunol 1997 Aug; 79(2): 163–72

    Article  PubMed  CAS  Google Scholar 

  182. Wilson AM, Orr LC, Sims EJ, et al. Effects of monotherapy with intra-nasal corticosteroid or combined oral histamine and leukotriene receptor antagonists in seasonal allergic rhinitis. Clin Exp Allergy 2001 Jan; 31(1): 61–8

    PubMed  CAS  Google Scholar 

  183. Wilson AM, Sims EJ, Orr LC, et al. Effects of topical corticosteroid and combined mediator blockade on domiciliary and laboratory measurements of nasal function in seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2001 Oct; 87(4): 344–9

    Article  PubMed  CAS  Google Scholar 

  184. Benincasa C, Lloyd RS. Evaluation of fluticasone propionate aqueous nasal spray taken alone and in combination with cetirizine in the prophylactic treatment of seasonal allergic rhinitis. Drug Invest 1994; 8(4): 225–33

    Article  Google Scholar 

  185. Gillman SA, Blatter M, Condemi JJ, et al. The health-related quality of life effects of once-daily cetirizine HC1 syrup in children with seasonal allergic rhinitis. Clin Pediatr (Phila) 2002 Nov–Dec; 41(9): 687–96

    Article  Google Scholar 

  186. Bousquet J, Duchateau J, Pignat JC, et al. Improvement of quality of life by treatment with cetirizine in patients with perennial allergic rhinitis as determined by a French version of the SF-36 questionnaire. J Allergy Clin Immunol 1996 Aug; 98(2): 309–16

    Article  PubMed  CAS  Google Scholar 

  187. Burtin B, Duchateau J, Pignat JC, et al. Further improvement of quality of life by cetirizine in perennial allergic rhinitis as a function of treatment duration. J Investig Allergol Clin Immunol 2000 Mar–Apr; 10(2): 66–70

    PubMed  CAS  Google Scholar 

  188. Lee EE, Maibach HI. Treatment of urticaria. An evidence-based evaluation of antihistamines. Am J Clin Dermatol 2001; 2(1): 27–32

    CAS  Google Scholar 

  189. Broide D. Clinical studies with cetirizine in allergic rhinitis and chronic urticaria. Allergy 1995; 50 Suppl. 24: 31–5

    Article  PubMed  CAS  Google Scholar 

  190. Kaplan AP. Chronic urticaria and angioedema. N Engl J Med 2002 Jan 17; 346(3): 175–9

    Article  PubMed  Google Scholar 

  191. Wanderer AA, Bernstein IL, Goodman DL, et al. The diagnosis and management of urticaria: a practice parameter. Ann Allergy Asthma Immunol 2000; 85 (6 Pt 2): S21–44

    Google Scholar 

  192. Greaves MW. Chronic idiopathic urticaria. Curr Opin Allergy Clin Immunol 2003; 3(5): 363–8

    Article  PubMed  Google Scholar 

  193. Abu Shareeah AM, Youssuf M, Deckers I, et al. Double-blind, parallel, randomized pilot study comparing the efficacy and tolerance of cetirizine 10 mg, mequitazine 2 × 5 mg and placebo in the treatment of patients suffering from chronic urticaria: comparison of suppressive effects on histamineinduced weals and flares. Drug Dev Res 1998 Apr; 43: 185–92

    Article  Google Scholar 

  194. Alomar A, De La Cuadra J, Fernandez J. Cetirizine vs astemizole in the treatment of chronic idiopathic urticaria. J Int Med Res 1990 Sep–Oct; 18(5): 358–65

    PubMed  CAS  Google Scholar 

  195. Andri L, Senna GE, Betteli C, et al. A comparison of the efficacy of cetirizine and terfenadine: a double-blind, controlled study of chronic idiopathic urticaria. Allergy 1993 Jul; 48(5): 358–65

    Article  PubMed  CAS  Google Scholar 

  196. Breneman D, Bronsky EA, Bruce S, et al. Cetirizine and astemizole therapy for chronic idiopathic urticaria: a double-blind, placebo-controlled, comparative trial. J Am Acad Dermatol 1995 Aug; 33 (2 Pt 1): 192–8

    Article  PubMed  CAS  Google Scholar 

  197. Breneman DL. Cetirizine versus hydroxyzine and placebo in chronic idiopathic urticaria. Ann Pharmacother 1996 Oct; 30(10): 1075–9

    PubMed  CAS  Google Scholar 

  198. Kalivas J, Breneman D, Tharp M, et al. Urticaria: clinical efficacy of cetirizine in comparison with hydroxyzine and placebo. J Allergy Clin Immunol 1990; 86 (6 Pt 2): 1014–8

    Article  PubMed  CAS  Google Scholar 

  199. Kietzmann H, Macher E, Rihoux JP, et al. Comparison of cetirizine and terfenadine in the treatment of chronic idiopathic urticaria. Ann Allergy 1990 Dec; 65(6): 498–500

    PubMed  CAS  Google Scholar 

  200. Parsad D, Pandhi R, Juneja A. Stanozolol in chronic urticaria: a double blind, placebo controlled trial. J Dermatol 2001 Jun; 28(6): 299–302

    PubMed  CAS  Google Scholar 

  201. Patel P, Danzig M. Comparative efficacy and safety of loratadine and cetirizine in patients with chronic idiopathic urticaria. Adv Ther 1997 Nov–Dec; 14(6): 318–22

    CAS  Google Scholar 

  202. La Rosa M, Leonardi S, Marchese G, et al. Double-blind multicenter study on the efficacy and tolerability of cetirizine compared with oxatomide in chronic idiopathic urticaria in preschool children. Ann Allergy Asthma Immunol 2001 Jul; 87(1): 48–53

    Article  PubMed  Google Scholar 

  203. Pacor ML, Di Lorenzo G, Corrocher R. Efficacy of leukotriene receptor antagonist in chronic urticaria. A double-blind, placebo-controlled comparison of treatment with montelukast and cetirizine in patients with chronic urticaria with intolerance to food additive and/or acetylsalicylic acid. Clin Exp Allergy 2001 Oct; 31(10): 1607–14

    PubMed  CAS  Google Scholar 

  204. Simons FE. Prevention of acute urticaria in young children with atopic dermatitis. J Allergy Clin Immunol 2001 Apr; 107(4): 703–6

    Article  PubMed  CAS  Google Scholar 

  205. Rudikoff D, Lebwohl M. Atopic dermatitis. Lancet 1998 Jun; 351(9117): 1715–21

    Article  PubMed  CAS  Google Scholar 

  206. Oranje AP, De Waard-Van Der Spek FB. Atopic dermatitis: review 2000 to January 2001. Curr Opin Pediatr 2002 Aug; 14(4): 410–3

    Article  PubMed  Google Scholar 

  207. Hannuksela M, Kalimo K, Lammintausta K, et al. Dose ranging study: cetirizine in the treatment of atopic dermatitis in adults. Ann Allergy 1993; 70(2): 127–33

    PubMed  CAS  Google Scholar 

  208. Patel P, Gratton D, Eckstein G, et al. A double-blind study of loratadine and cetirizine in atopic dermatitis. J Dermatol Treat 1997; 8(4): 249–53

    Article  Google Scholar 

  209. La Rosa M, Ranno C, Musarra I, et al. Double-blind study of cetirizine in atopic eczema in children. Ann Allergy 1994 Aug; 73(2): 117–22

    PubMed  Google Scholar 

  210. Diepgen TL. Long-term treatment with cetirizine of infants with atopic dermatitis: a multi-country, double-blind, randomized, placebo-controlled trial (the ETAC trial) over 18 months. Pediatr Allergy Immunol 2002 Aug; 13(4): 278–86

    Article  PubMed  Google Scholar 

  211. Consensus report of the European task force on atopic dermatology. Severity scoring of atopic dermatitis: the SOCRAD index. Dermatology 1993; 186: 23–31

    Article  Google Scholar 

  212. Bergmann RL, Edenharter G, Bergmann KE, et al. Atopic dermatitis in early infancy predicts allergic airway disease at 5 years. Clin Exp Allergy 1998 Aug; 28(8): 965–70

    Article  PubMed  CAS  Google Scholar 

  213. Castro-Rodriguez JA, Holberg CJ, Wright AL. A clinical index to define risk of asthma in young children with recurrent wheezing. Am J Respir Crit Care Med 2000 Oct; 162 (4 Pt 1): 1403–6

    PubMed  CAS  Google Scholar 

  214. Bousquet J, van Cauwenberge P, Khaltaev N, et al. Allergic rhinitis and its impact on asthma (ARIA): in collaboration with the World Health Organization. Allergy 2002; 57(9): 841–55

    Article  PubMed  Google Scholar 

  215. Stanciu LA, Djukanovic R. The role of ICAM-1 on T-cells in the pathogenesis of asthma. Eur Respir J 1998 Apr; 11(4): 949–57

    Article  PubMed  CAS  Google Scholar 

  216. Nelson HS. Prospects for antihistamines in the treatment of asthma. J Allergy Clin Immunol 2003 Oct; 112 (4 Suppl.): S96–S100

    Article  PubMed  CAS  Google Scholar 

  217. Larsen JS. Do antihistamines have a role in asthma therapy? Pharmacotherapy 2001; 21 (3 Pt 2): 28S–33S

    Article  PubMed  CAS  Google Scholar 

  218. Mincarini M, Pasquali M, Cosentino C, et al. Antihistamines in the treatment of bronchial asthma. Present knowledge and future perspectives. Pulm Pharmacol Ther 2001; 14(4): 267–76

    CAS  Google Scholar 

  219. Aaronson DW. Evaluation of cetirizine in patients with allergic rhinitis and perennial asthma. Ann Allergy Asthma Immunol 1996 May; 76(5): 440–6

    Article  PubMed  CAS  Google Scholar 

  220. Bruttmann G, Pedrali P, Arendt C, et al. Protective effect of cetirizine in patients suffering from pollen asthma. Ann Allergy 1990 Feb; 64 (2 Pt 2): 224–8

    PubMed  CAS  Google Scholar 

  221. Bousquet J, Emonot A, Germouty J, et al. Double-blind multicenter study of cetirizine in grass-pollen-induced asthma. Ann Allergy 1990; 65(6): 504–8

    PubMed  CAS  Google Scholar 

  222. Dijkman JH, Hekking PRM, Molkenboer JF, et al. Prophylactic treatment of grass pollen-induced asthma with cetirizine. J Clin Exp Allergy 1990; 20(5): 483–90

    Article  CAS  Google Scholar 

  223. Spector SL, Nicodemus CF, Corren J, et al. Comparison of the bronchodilatory effects of cetirizine, albuterol, and both together versus placebo in patients with mild-to-moderate asthma. J Allergy Clin Immunol 1995 Aug; 96(2): 174–81

    Article  PubMed  CAS  Google Scholar 

  224. ETAC Study Group. Allergic factors associated with the development of asthma and the influence of cetirizine in a double-blind, randomised, placebo-controlled trial: first results of ETAC. Early Treatment of the Atopic Child. Pediatr Allergy Immunol 1998 Aug; 9(3): 116–24

    Google Scholar 

  225. Warner JO. A double-blinded, randomized, placebo-controlled trial of cetirizine in preventing the onset of asthma in children with atopic dermatitis: 18 months’ treatment and 18 months’ posttreatment follow-up. ETAC Study Group. J Allergy Clin Immunol 2001 Dec; 108(6): 929–37

    Article  CAS  Google Scholar 

  226. Ciprandi G, Tosca M, Ricca V, et al. Cetirizine treatment of rhinitis in children with pollen allergy: evidence of its antiallergic activity. Clin Exp Allergy 1997 Oct; 27(10): 1160–6

    Article  PubMed  CAS  Google Scholar 

  227. Reunala T, Brummer-Korvenkontio H, Palosuo T. Are we really allergic to mosquito bites? Ann Med 1994 Aug; 26(4): 301–6

    Article  PubMed  CAS  Google Scholar 

  228. Reunala T, Lappalainen P, Brummer-Korvenkontio H, et al. Cutaneous reactivity to mosquito bites: effect of cetirizine and development of anti-mosquito antibodies. Clin Exp Allergy 1991 Sept; 21(5): 617–22

    Article  PubMed  CAS  Google Scholar 

  229. Reunala T, Brummer-Korvenkontio H, Karppinen A, et al. Treatment of mosquito bites with cetirizine. Clin Exp Allergy 1993 Jan; 23(1): 72–5

    Article  PubMed  CAS  Google Scholar 

  230. Karppinen A, Kautiainen H, Petman L, et al. Comparison of cetirizine, ebastine and loratadine in the treatment of immediate mosquito-bite allergy. Allergy 2002 Jun; 57(6): 534–7

    Article  PubMed  CAS  Google Scholar 

  231. Mann RD, Pearce GL, Dunn N, et al. Sedation with “nonsedating” antihistamines: four prescription-event monitoring studies in general practice. BMJ 2000 Apr 29; 320(7243): 1184–6

    Article  PubMed  CAS  Google Scholar 

  232. Spiller HA, Villalobos D, Benson BE, et al. Retrospective evaluation of cetirizine (Zyrtec®) ingestion [letter]. J Toxicol Clin Toxicol 2002; 40(4): 525–6

    PubMed  Google Scholar 

  233. Bäckström M, Lennestål R, Nilsson NA. Treatment with Zyrlex (cetirizine) led to severe liver reaction. Med Prod Agency 2001 Apr, 43

  234. Sanchez-Lombrana JL, Alvarez RP, Saez LR, et al. Acute hepatitis associated with cetirizine intake [letter]. J Clin Gastroenterol 2002 Apr; 34(4): 493–5

    Article  PubMed  Google Scholar 

  235. Watanabe M, Kohge N, Kaji T. Severe hepatitis in a patient taking cetirizine [letter]. Ann Intern Med 2001 Jul 17; 135(2): 142–3

    PubMed  CAS  Google Scholar 

  236. Bera F, Siproudhis JP, Jonville-Bera AP, et al. Hepatic injury after cetirizine administration [letter; in French]. Gastroenterol Clin Biol 1993; 17(10): 770–1

    PubMed  CAS  Google Scholar 

  237. Fong DG, Angulo P, Burgart LJ, et al. Cetirizine-induce cholestasis. J Clin Gastroenterol 2000 Oct; 31(3): 250–3

    Article  PubMed  CAS  Google Scholar 

  238. Calista D, Schianchi S, Morri M. Urticaria induced by cetirizine. Br J Dermatol 2001 Jan; 144(1): 196

    PubMed  CAS  Google Scholar 

  239. Telia R, Gaig P, Bartra J, et al. Urticaria to cetirizine. J Investig Allergol Clin Immunol 2002; 12(2): 136–7

    Google Scholar 

  240. Karamfilov T, Wilmer A, Hipler UC, et al. Cetirizine-induced urticarial reaction [letter]. Br J Dermatol 1999 May; 140(5): 979–80

    Article  PubMed  CAS  Google Scholar 

  241. Schröter S, Damveld B, Marsch WC. Urticarial intolerance reaction to cetirizine. Clin Exp Dermatol 2002 May; 27(3): 185–7

    Article  PubMed  Google Scholar 

  242. Kranke B, Kern T. Multilocalized fixed drug eruption to the antihistamine cetirizine [letter]. J Allergy Clin Immunol 2000 Nov; 106(5): 988

    Article  PubMed  CAS  Google Scholar 

  243. Einarson A, Bailey B, Jung G, et al. Prospective controlled study of hydroxyzine and cetirizine in pregnancy. Ann Allergy Asthma Immunol 1997 Feb; 78(2): 183–6

    Article  PubMed  CAS  Google Scholar 

  244. Delgado LF, Pferferman A, Sole D, et al. Evaluation of the potential cardiotoxicity of the antihistamines terfenadine, astemizole, loratadine, and cetirizine in atopic children. Ann Allergy Asthma Immunol 1998 Apr; 80(4): 333–7

    Article  PubMed  CAS  Google Scholar 

  245. Ridout SM, Tariq SM. Cetirizine overdose in a young child [letter]. J Allergy Clin Immunol 1997 Jun; 99 (6 Pt 1.): 860–1

    Article  PubMed  CAS  Google Scholar 

  246. Hansen JJ, Feilberg Jorgensen NH. Accidental cetirizine poisoning in a four-year-old boy [in Danish]. Ugeskrift Laeger 1998; 160: 5946–7

    CAS  Google Scholar 

  247. UCB Pharma Limited. Zirtek® allergy tablet (UK prescribing information) 2003 Feb [online]. Available from URL: http://www.emc.medicines.org.uk [Accessed 2003 Oct 14]

  248. UCB Pharma Limited. Zirtek® allergy solution (UK prescribing information) 2003 Jan [online]. Available from URL: http://www.emc.medicine.org.uk [Accessed 2003 Oct 14]

  249. Fornadley JA, Corey JP, Osguthorpe JD, et al. Allergic rhinitis: clinical practice guideline. Committee on Practice Standards, American Academy of Otolaryngic Allergy. Otolaryngol Head Neck Surg 1996 Jul; 115(1): 115–22

    Article  CAS  Google Scholar 

  250. Schoenwetter WF. Allergic rhinitis: epidemiology and natural history. Allergy Asthma Proc 2000 Jan–Feb; 21(1): 1–6

    Article  PubMed  CAS  Google Scholar 

  251. Stachen DP, Sibbald B, Weiland SK, et al. Worldwide variation in the prevalence of symptoms of allergic rhinoconjunctivitis in childhood: the International Study of Asthma and Allergies in Childhood (ISACC). Pediatr Allergy Immunol 1997 Nov; 8(4): 161–76

    Article  Google Scholar 

  252. Blaiss MS. Quality of life in allergic rhinitis. Ann Allergy Asthma Immunol 1999 Nov; 83(5): 449–54

    Article  PubMed  CAS  Google Scholar 

  253. Juniper EF. Quality of life in adults and children with asthma and rhinitis. Allergy 1997; 52: 971–7

    Article  PubMed  CAS  Google Scholar 

  254. Dykewicz MS, Fineman S, Skoner DP, et al. Diagnosis and management of rhinitis: complete guidelines of the Joint Task Force on Practice Parameters in Allergy, Asthma and Immunology. American Academy of Allergy, Asthma, and Immunology. Ann Allergy Asthma Immunol 1998; 81 (5 Pt 2): 478–518

    Article  PubMed  CAS  Google Scholar 

  255. Malone DC, Lawson KA, Smith DH, et al. A cost of illness study of allergic rhinitis in the United States. J Allergy Clin Immunol 1997 Jan; 99 (1 Pt 1): 22–7

    PubMed  CAS  Google Scholar 

  256. Simons FE. Learning impairment and allergic rhinitis. Allergy Asthma Proc 1996 Jul–Aug; 17(4): 185–9

    Article  PubMed  CAS  Google Scholar 

  257. Handley DA, Magnetti A, Higgins AJ. Therapeutic advantages of third generation antihistamines. Expert Opin Invest Drugs 1998 Jul; 7: 1045–54

    Article  CAS  Google Scholar 

  258. Simons FE, Simons KJ. The pharmacology and use of H1-receptor-antagonist drugs. N Engl J Med 1994 Jun 9; 330(23): 1663–70

    Article  PubMed  CAS  Google Scholar 

  259. Casale TB, Blaiss MS, Gelfand E, et al. First do no harm: managing antihistamine impairment in patients with allergic rhinitis. J Allergy Clin Immunol 2003 May; 111(5): 835–42

    Article  Google Scholar 

  260. Simons FER. H1-receptor antagonists: safety issues. Ann Allergy Asthma Immunol 1999 Nov; 83(5): 481–8

    Article  PubMed  CAS  Google Scholar 

  261. Grattan C, Powell S, Humphreys F. Management and diagnostic guidelines for urticaria and angio-oedema. Br J Dermatol 2001 Apr; 144: 708–14

    Article  PubMed  CAS  Google Scholar 

  262. Sharma JK, Miller R, Murray S. Chronic urticaria: a Canadian perspective on patterns and practical management strategies. J Cutan Med Surg 2000 Apr; 4(2): 89–93

    PubMed  CAS  Google Scholar 

  263. Tharp MD. Chronic urticaria: pathophysiology and treatment approaches. J Allergy Clin Immunol 1996 Dec; 98 (6 Pt 3): S325–30

    PubMed  CAS  Google Scholar 

  264. Wilson AM. Are antihistamines useful in managing asthma? Curr Opin Allergy Clin Immunol 2002 Feb; 2(1): 53–9

    Article  PubMed  Google Scholar 

  265. Walsh GM. Second-generation antihistamines in asthma therapy: is there a protective effect? Am J Resp Med 2002; 1(1): 27–34

    Article  CAS  Google Scholar 

  266. Lin H, Casale TB. Treatment of allergic asthma. Am J Med 2002; 113 Suppl. 9A: 8S–16S

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Adis International Limited, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, Auckland, 1311, New Zealand

    Monique P. Curran, Lesley J. Scott & Caroline M. Perry

Authors
  1. Monique P. Curran
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lesley J. Scott
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Caroline M. Perry
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Monique P. Curran.

Additional information

Various sections of the manuscript reviewed by: B.G. Bender, National Jewish Medical and Research Center, Denver, Colorado, USA; J.H. Day, Kingston General Hospital, Kingston, Ontario, Canada; D. Reichmuth, Allergy and Asthma Care of Florida, Ocala, Florida, USA; R.F. Lockey, University of South Florida of Medicine, Tampa, Florida, USA; F.E.R. Simons, Children’s Hospital of Winnipeg, Winnipeg, Manitoba, Canada; G.M. Walsh, University of Aberdeen Medical School, Aberdeen, UK; J.O. Warner, University of Southampton, Southampton, UK.

Data Selection

Sources: Medical literature published in any language since 1980 on cetirizine, identified using Medline and EMBASE, supplemented by AdisBase (a proprietary database of Adis International). Additional references were identified from the reference lists of published articles. Bibliographical information, including contributory unpublished data, was also requested from the company developing the drug.

Search strategy: Medline search terms were ‘cetirizine’. EMBASE search terms were ‘cetirizine’. AdisBase search terms were ‘cetirizine’. Searches were last updated 1 February 2003.

Selection: Studies in patients with allergic disorders who received cetirizine. Inclusion of studies was based mainly on the methods section of the trials. When available, large, well controlled trials with appropriate statistical methodology were preferred. Relevant pharmacodynamic and pharmacokinetic data are also included.

Index terms: cetirizine, allergic disorders, allergic rhinitis, asthma, atopic dermatitis, pharmacodynamics, pharmacokinetics, therapeutic use, tolerability, urticaria.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Curran, M.P., Scott, L.J. & Perry, C.M. Cetirizine. Drugs 64, 523–561 (2004). https://doi.org/10.2165/00003495-200464050-00008

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200464050-00008

Keywords

Search

Navigation